Brief: Phio Pharmaceuticals Presents Anti-Tumor Immunity Data
16/09/2021 12:09
Sept 16 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS PRESENTS DATA AT ESMO 2021
DEMONSTRATING
PERSISTENT ANTI-TUMOR IMMUNITY WITH INTASYL DUAL-TARGETING PD-1
AND BRD4
* PHIO PHARMACEUTICALS CORP - LOCAL TREATMENT WITH PD-1 AND
BRD4
DUAL-TARGETING INTASYL ALSO SHOWED COMPLETE RESOLUTION OF TUMORS
IN VIVO
Source text for Eikon: ID:nPnb4fldNa
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing